Phenotypic and Functional Characteristics of Blood Natural Killer Cells from Melanoma Patients at Different Clinical Stages

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Fregni, Giulia ^a,e   Messaoudene, Meriem ^a   Fourmentraux Neves, Emmanuelle ^a   Mazouz Dorval, Sarra ^a   Chanal, Johan ^a,b   Maubec, Eve ^c   Marinho, Eduardo ^c   Scheer Senyarich, Isabelle ^c   Cremer, Isabelle ^d   Avril, Marie Françoise ^a,b   Caignard, Anne ^a  

^a INSTITUT COCHIN   (France)

^b Department of Dermatology Cochin Hospital ^*  (France)

^c BICHAT HOSPITAL   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR NKG2D;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL COUNT; CELL FUNCTION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGRANULATION; DISEASE SEVERITY; ENZYME ACTIVATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA; MELANOMA CELL; METASTASIS POTENTIAL; NATURAL KILLER CELL; PHENOTYPE; PROTEIN EXPRESSION; SINGLE CELL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CELL DEGRANULATION; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NEOPLASM STAGING; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84885697105     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076928     Document Type: Article

References (43)

1. Trinchieri G, (1989) Biology of natural killer cells. Adv Immunol 47: 187-376.
2. Moretta L, Moretta A, (2004) Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 23: 255-259.
3. Caligiuri MA, (2008) Human natural killer cells. Blood 112: 461-469.
4. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, et al. (2006) Surface NK receptors and their ligands on tumor cells. Semin Immunol 18: 151-158.
5. Moretta L, Moretta A, (2004) Killer immunoglobulin-like receptors. Curr Opin Immunol 16: 626-633.
6. Lopez-Botet M, M MC, T TB, Perez-Villar J, Llano M, et al. (1998) The CD94/NKG2 C-type lectin receptor complex. Curr Top Microbiol Immunol 230: 41-52.
7. Long EO, (1999) Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 17: 875-904.
8. Kornstein MJ, Stewart R, Elder DE, (1987) Natural killer cells in the host response to melanoma. Cancer Res 47: 1411-1412.
9. Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, et al. (2006) Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 12: 718-725.
10. McKay K, Moore PC, Smoller BR, Hiatt KM, (2011) Association between natural killer cells and regression in melanocytic lesions. Hum Pathol 42: 1960-1964.
11. Ferradini L, Mackensen A, Genevee C, Bosq J, Duvillard P, et al. (1993) Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest 91: 1183-1190.
12. Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, et al. (2004) Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res 64: 2192-2198.
13. Wang E, Phan GQ, Marincola FM, (2001) T-cell-directed cancer vaccines: the melanoma model. Expert Opin Biol Ther 1: 277-290.
14. Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X, et al. (2011) Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res 17: 2628-2637.
15. Zhu J, Wang X, Xu X, Abassi YA, (2006) Dynamic and label-free monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays. J Immunol Methods 309: 25-33.
16. Perier A, Fregni G, Wittnebel S, Gad S, Allard M, et al. (2011) Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Oncogene 30: 2622-2632.
17. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, et al. (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71: 5412-5422.
18. Pittari G, Fregni G, Roguet L, Garcia A, Vataire AL, et al. (2010) Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients. Bone Marrow Transplant 45: 862-871.
19. Mirjacic Martinovic K, Konjevic G, Babovic N, Inic M, (2011) The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients. J Surg Res 171: 637-649.
20. Konjevic G, Mirjacic Martinovic K, Vuletic A, Jovic V, Jurisic V, et al. (2007) Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 24: 1-11.
21. Konjevic G, Mirjacic Martinovic K, Vuletic A, Radenkovic S, (2010) Novel aspects of in vitro IL-2 or IFN-alpha enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction. Biomed Pharmacother 64: 663-671.
22. Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, et al. (2011) Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res 71: 6621-6632.
23. Fregni G, Perier A, Avril MF, Caignard A, (2012) NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies. Oncoimmunology 1: 38-47.
24. Vetter CS, Straten PT, Terheyden P, Zeuthen J, Brocker EB, et al. (2000) Expression of CD94/NKG2 subtypes on tumor-infiltrating lymphocytes in primary and metastatic melanoma. J Invest Dermatol 114: 941-947.
25. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, et al. (2012) Immunotype and Immunohistologic Characteristics of Tumor Infiltrating Immune Cells are Associated with Clinical Outcome in Metastatic Melanoma. Cancer Res.
26. Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, et al. (2013) Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res.
27. Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, et al. (2013) Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors. Cancer Res 73: 3499-3510.
28. Glasner A, Ghadially H, Gur C, Stanietsky N, Tsukerman P, et al. (2012) Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J Immunol 188: 2509-2515.
29. Halfteck GG, Elboim M, Gur C, Achdout H, Ghadially H, et al. (2009) Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J Immunol 182: 2221-2230.
30. Cagnano E, Hershkovitz O, Zilka A, Bar-Ilan A, Golder A, et al. (2008) Expression of ligands to NKp46 in benign and malignant melanocytes. J Invest Dermatol 128: 972-979.
31. Elliott JM, Wahle JA, Yokoyama WM, (2010) MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med 207: 2073-2079.
32. Joncker NT, Shifrin N, Delebecque F, Raulet DH, (2010) Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med 207: 2065-2072.
33. Sun JC, Beilke JN, Bezman NA, Lanier LL, (2011) Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. J Exp Med 208: 357-368.
34. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, et al. (2009) NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest.
35. Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, et al. (2006) The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 108: 4118-4125.
36. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, et al. (2012) Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res.
37. Coupel S, Moreau A, Hamidou M, Horejsi V, Soulillou JP, et al. (2007) Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood 109: 2806-2814.
38. Allard M, Oger R, Vignard V, Percier JM, Fregni G, et al. (2011) Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One 6: e21118.
39. McCarter M, Clarke J, Richter D, Wilson C, (2005) Melanoma skews dendritic cells to facilitate a T helper 2 profile. Surgery 138: 321-328.
40. Godefroy E, Manches O, Dreno B, Hochman T, Rolnitzky L, et al. (2011) Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell 19: 333-346.
41. Miller G, Lahrs S, Dematteo RP, (2003) Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity. FASEB J 17: 728-730.
42. Wong JL, Mailliard RB, Moschos SJ, Edington H, Lotze MT, et al. (2011) Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother 34: 270-278.
43. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.